Starpharma (ASX:SPL) share price slips after posting loss

The Starpharma (ASX: SPL) share price has dipped today after the company reported a $10 million loss. Here are the details.

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price is in the red today, slipping 0.47% at the time of writing to $2.13.

The biotechnology company develops new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery, VivaGel and Viraleze.

 Stapharma reported its half-year results earlier today. This is what we found out.

Starpharma posts half-year losses

Starpharma reported that its total revenue for the first half of FY21 (1H21) was $638,000, down 89% on the previous corresponding period.

The company also incurred a loss after tax of $10.4 million in 1H21, which was 78% greater than that incurred in 1H20. It attributed the loss to lower revenue generated during the period.

Basic loss per share was $2.69 in 1H21 compared to a loss per share of $1.58 in 1H20.

However, Starpharma's net assets more than doubled during the period and it finished off the half with a value of $69.9 million. In contrast to $31.3 million net assets in 1H20.

The cash balance as of 31 December 2021 was $70.3 million, a significant leap from $35.9 million at the end of 1HY20.

CEO commentary

Starpharma CEO Dr Jackie Fairley said the company "achieved multiple significant milestones in the recent period". These included the rapid development of its Viraleze antiviral nasal spray and signing two new partnerships:

These new partnerships illustrate the broad applicability of the DEP® platform and its use for multiple therapeutic areas.

We also progressed our other partnered DEP® programs and recently announced AstraZeneca's global expansion of its phase 1 trial for DEP® AZD0466 which is designed to expedite the development of this exciting novel drug.

Dr Fairley also advised that additional clinical trial programs were progressing as the company continued to focus on expanding the availability of its products.

Starpharma share price snapshot

The Starpharma share price has gained 89.09% over the past year.

There are currently 406 million shares outstanding. The Starpharma market capitalisation presently stands at $897.3 million.

Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A view of competitors in a running event, some wearing number bibs, line up together on a starting line looking ahead as if to start a race.
Technology Shares

Here's how the ASX 200 market sectors stacked up last week

ASX technology shares led the market with a 2.48% increase last week.

Read more »

A father helps his son look through binoculars during a family holiday or day out in the city.
Opinions

Up 190% in a year, why I think Life360 shares can keep soaring higher

This tech stock has plenty of potential.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Magnifying glass on a rising interest rate graph.
Share Market News

Will the RBA finally cut interest rates next week?

Let's see what economists are saying about the central bank's meeting.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors endured a rough Friday to close the trading week today.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Broker Notes

7 ASX All Ords shares elevated to 'strong buy' status in October

The brokers turned bullish on these ASX companies last month.

Read more »

A businessman compares the growth trajectory of property versus shares.
Share Market News

How ASX shares vs. property performed in October

The national home value rose for the 21st consecutive month while the ASX 200 dipped.

Read more »